Barriers and Facilitators of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
This study using a mixed-methods approach with quantitative and qualitative components found that the issues underlying TI underutilization were numerous and multifactorial; the barriers encountered by physicians and the resources to help address them varied by specialty. These findings offer insights into physician-supported strategies that could help improve rates of first-line TI for mCSPC in the US.
Authors
- Janet Kim
- Sarah Rich-Zendel
- Stacy Loeb (ORCID: https://orcid.org/0000-0003-3933-9207)
- J. H. Sheldon (ORCID: https://orcid.org/0000-0001-9934-461X)
- Laura de Ruiter (ORCID: https://orcid.org/0000-0002-6590-4073)
- Nader N. El-Chaar
- Jin Su Joo (ORCID: https://orcid.org/0000-0003-2832-1597)
- Betty Thompson
- Judith Dyson (ORCID: https://orcid.org/0000-0002-0928-0438)
- Jesse Mack
- Neeraj Agarwal
Institutions
- Birmingham City University (GB)
- Pfizer (United States) (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- NYU Langone Health (US)
- Breakthrough (US)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.35728
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00